港股異動 | 開拓藥業-B(9939.HK)升超7%再創歷史新高 年內股價翻逾6倍
格隆匯4月27日丨開拓藥業-B(9939.HK)延續強勢行情,再度上漲7.12%,報64.5港元續創歷史新高,總市值近240億港元。該股年內已暴漲超500%,股價翻逾6倍。開拓藥業26日公佈,獲得美國FDA批准的普克魯胺治療輕中症新冠男性患者的III期臨牀試驗已在美國的臨牀中心完成首例受試者入組及給藥。普克魯胺獲得美國FDA同意啟動治療新冠的註冊性III期臨牀試驗,對於開拓藥業來説是一個重大里程碑。計劃在美國、歐盟、南非和巴西等國開展多國多中心的普克魯胺治療輕中症新冠男性患者的III期臨牀試驗。據瞭解,公司在全球擁有已獲得及申請中的60多項專利,多個項目被列為國家十二五、十三五“重大新藥創制”專項。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.